Safety and Immunogenicity of an MF59-adjuvanted Subunit Influenza Vaccine in Elderly Chinese Subjects

Overview

Journal Immun Ageing

Publisher Biomed Central

Specialty Geriatrics

Date 2008 Feb 22

PMID 18289372

Citations 11

Authors

Rongcheng Li

Hanhua Fang

Yanping Li

Youping Liu

Michele Pellegrini

Audino Podda

Affiliations

Soon will be listed here.

Abstract

Background: The safety and immunogenicity of an MF59-adjuvanted subunit influenza vaccine (Sub/MF59; FLUAD, Novartis Vaccines) was evaluated among elderly Chinese subjects (> or = 60 years of age). After a preliminary Phase I, open-label study (n = 25) to assess safety 1-14 days post-vaccination, a comparative observer-blind, randomised, controlled clinical trial (n = 600) was performed to assess safety and immunogenicity versus a non-adjuvanted subunit influenza vaccine (Subunit; Agrippal, Novartis Vaccines). Subjects were randomised (2:1) to receive Sub/MF59 or Subunit.

Results: Both vaccines were well tolerated, with no vaccine-related serious adverse events reported during the Phase I trial. During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1-22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59 recipients (P < or = 0.005). Both vaccines induced a significant (P < 0.001) increase in geometric mean titres (GMTs) for the three strains tested, versus baseline; GMTs against A/H1N1, A/H3N2 and B were significantly higher in the Sub/MF59 group (P = 0.034, P < 0.001 and P = 0.005, respectively). GMT ratios against A/H1N1, A/H3N2 and B were also significantly higher in the Sub/MF59 group (P = 0.038, P < 0.001 and P = 0.006, respectively). Similarly, the percentage of subjects achieving seroprotection or seroconversion on Day 22 was greater for Sub/MF59 recipients, reaching significance for A/H3N2 (P < 0.001).

Conclusion: MF59-adjuvanted subunit influenza vaccine is well tolerated by elderly Chinese subjects and induces a higher level of immunogenicity than a non-adjuvanted subunit influenza vaccine in this population that is at high risk of influenza-related complications.

Clinical Trial Registry: http://www.clinicaltrials.gov, NCT00310648.

Citing Articles

Relative Efficacy, Effectiveness and Safety of Newer and/or Enhanced Seasonal Influenza Vaccines for the Prevention of Laboratory-Confirmed Influenza in Individuals Aged 18 years and Over: Update of a Systematic Review.

Askar M, Ali K, Batke M, Brugger T, Falman A, Robertson A Rev Med Virol. 2025; 35(2):e70020.

PMID: 39994168 PMC: 11850296. DOI: 10.1002/rmv.70020.

[Health Technology Assessment: a value-based tool for the evaluation of healthcare technologies. Reassessment of the cell-culture-derived quadrivalent influenza vaccine: Flucelvax Tetra 2.0].

Calabro G, Boccalini S, Bechini A, Panatto D, Domnich A, Lai P J Prev Med Hyg. 2023; 63(4 Suppl 1):E1-E140.

PMID: 37034835 PMC: 10079375. DOI: 10.15167/2421-4248/jpmh2022.63.4s1.

Recommendations on the use of MF59-Adjuvanted Trivalent Influenza Vaccine (Fluad): Supplemental Statement of Seasonal Influenza Vaccine for 2011-2012 An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Can Commun Dis Rep. 2019; 37(ACS-6):1-68.

PMID: 31701945 PMC: 6802457. DOI: 10.14745/ccdr.v37i00a06.

Enhanced Passive Safety Surveillance (EPSS) confirms an optimal safety profile of the use of MF59 -adjuvanted influenza vaccine in older adults: Results from three consecutive seasons.

Panatto D, Haag M, Lai P, Tomczyk S, Amicizia D, Lino M Influenza Other Respir Viruses. 2019; 14(1):61-66.

PMID: 31617965 PMC: 6928029. DOI: 10.1111/irv.12685.

Comparative Immunogenicity of Enhanced Seasonal Influenza Vaccines in Older Adults: A Systematic Review and Meta-analysis.

Ng T, Cowling B, Gao H, Thompson M J Infect Dis. 2018; 219(10):1525-1535.

PMID: 30551178 PMC: 6775043. DOI: 10.1093/infdis/jiy720.

References

Iob A, Brianti G, Zamparo E, Gallo T . Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiol Infect. 2005; 133(4):687-93. PMC: 2870297. DOI: 10.1017/s0950268805003936. View

Del Giudice G, Hilbert A, Bugarini R, Minutello A, Popova O, Toneatto D . An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine. 2006; 24(16):3063-5. DOI: 10.1016/j.vaccine.2006.01.015. View

Hsieh Y, Chen H, Yen J, Liu D, Chang L, Lu C . Influenza in Taiwan: seasonality and vaccine strain match. J Microbiol Immunol Infect. 2005; 38(4):238-43. View

Wong C, Chan K, Hedley A, Peiris J . Influenza-associated mortality in Hong Kong. Clin Infect Dis. 2004; 39(11):1611-7. DOI: 10.1086/425315. View

OHagan D . MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines. 2007; 6(5):699-710. DOI: 10.1586/14760584.6.5.699. View

Targonski P, Jacobson R, Poland G . Immunosenescence: role and measurement in influenza vaccine response among the elderly. Vaccine. 2007; 25(16):3066-9. DOI: 10.1016/j.vaccine.2007.01.025. View

Nichol K . The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine. 2003; 21(16):1769-75. DOI: 10.1016/s0264-410x(03)00070-7. View

Gardner E, Gonzalez E, Nogusa S, Murasko D . Age-related changes in the immune response to influenza vaccination in a racially diverse, healthy elderly population. Vaccine. 2005; 24(10):1609-14. DOI: 10.1016/j.vaccine.2005.09.058. View

Puig-Barbera J, Diez-Domingo J, Belenguer Varea A, Schwarz Chavarri G, Rodrigo J, Perez Hoyos S . Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine. 2007; 25(42):7313-21. DOI: 10.1016/j.vaccine.2007.08.039. View

10.

Banzhoff A, Nacci P, Podda A . A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology. 2003; 49(3):177-84. DOI: 10.1159/000069172. View

11.

Goodwin K, Viboud C, Simonsen L . Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2005; 24(8):1159-69. DOI: 10.1016/j.vaccine.2005.08.105. View

12.

Fiore A, Shay D, Haber P, Iskander J, Uyeki T, Mootrey G . Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm Rep. 2007; 56(RR-6):1-54. View

13.

Wang C, Wang S, Lai C, Lin L, Chou P . Impact of influenza vaccination on major cause-specific mortality. Vaccine. 2006; 25(7):1196-203. DOI: 10.1016/j.vaccine.2006.10.015. View

14.

Baldo V, Menegon T, Bonello C, Floreani A, Trivello R . Comparison of three different influenza vaccines in institutionalised elderly. Vaccine. 2001; 19(25-26):3472-5. DOI: 10.1016/s0264-410x(01)00060-3. View

15.

He J, Gu D, Wu X, Reynolds K, Duan X, Yao C . Major causes of death among men and women in China. N Engl J Med. 2005; 353(11):1124-34. DOI: 10.1056/NEJMsa050467. View

16.

Shortridge K . Severe acute respiratory syndrome and influenza: virus incursions from southern China. Am J Respir Crit Care Med. 2003; 168(12):1416-20. DOI: 10.1164/rccm.2310005. View

17.

Hui S, Chu L, Peiris J, Chan K, Chu D, Tsui W . Immune response to influenza vaccination in community-dwelling Chinese elderly persons. Vaccine. 2006; 24(25):5371-80. DOI: 10.1016/j.vaccine.2006.04.032. View

18.

Webster R . Predictions for future human influenza pandemics. J Infect Dis. 1997; 176 Suppl 1:S14-9. DOI: 10.1086/514168. View

19.

Podda A . The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine. 2001; 19(17-19):2673-80. DOI: 10.1016/s0264-410x(00)00499-0. View

20.

Puig-Barbera J, Diez-Domingo J, Perez Hoyos S, Belenguer Varea A, Gonzalez Vidal D . Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. Vaccine. 2004; 23(3):283-9. DOI: 10.1016/j.vaccine.2004.07.017. View